The largest database of trusted experimental protocols
> Chemicals & Drugs > Pharmacologic Substance > Fibrinolytic Agents

Fibrinolytic Agents

Fibrinolytic Agents: Substances that promote the breakdown of fibrin, the insoluble protein that forms the framework of a blood clot.
These agents, including thrombolytics and antifibrinolytics, play a crucial role in the management of various thrombotic disorders.
Researchers can explore the power of Fibrinolytic Agents using PubCompare.ai's AI-powered comparison and optimization tools, locating the best protocols from literature, pre-prihts, and patents, while enhancing reproducibility and research accuracy.
Discover the ideal Fibrinolytic Agents for your project with PubCompare.ai's intuitive platform.

Most cited protocols related to «Fibrinolytic Agents»

Venous blood drawn from healthy volunteers (n = 20) was transferred in different pre weighed sterile microcentrifuge tube (500 μl/tube) and incubated at 37°C for 45 minutes. After clot formation, serum was completely removed (aspirated out without disturbing the clot formed) and each tube having clot was again weighed to determine the clot weight (clot weight = weight of clot containing tube – weight of tube alone). Each microcentrifuge tube containing clot was properly labeled and 100 μl of streptokinase along with various dilutions in sterile distilled water (undiluted, 3:4, 1:2 and 1:3) was added to the tubes. Water was also added to one of the tubes containing clot and this serves as a negative thrombolytic control. All the tubes were then incubated at 37°C for 90 minutes and observed for clot lysis. After incubation, fluid obtained was removed and tubes were again weighed to observe the difference in weight after clot disruption. Difference obtained in weight taken before and after clot lysis was expressed as percentage of clot lysis. The test was repeated ten times with all the four dilutions of the thrombolytic drugs (Streptokinase) in blood samples of twenty different healthy volunteers.
Full text: Click here
Publication 2006
BLOOD Clotrimazole Fibrinolytic Agents Healthy Volunteers Serum Sterility, Reproductive Streptokinase Technique, Dilution Veins

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Acute Cerebrovascular Accidents Alteplase Brain Cerebrovascular Accident Eligibility Determination Ethics Committees, Research Feelings Fibrinolytic Agents Intracranial Hemorrhage Neoplasms Patients Placebos

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Alteplase Biological Factors BLOOD citrate phosphate dextrose Citrates Citric Acid Clotrimazole Coagulation, Blood Fibrinolytic Agents Glucose Homo sapiens Microbubbles Pigs Retractions, Clot Serum Susceptibility, Disease Therapies, Investigational Thrombus Tissue Donors Ultrasonography Veins
We created a web-based survey instrument that randomly assigned participants to see a picture of a black or white patient while reading a clinical vignette. From hundreds of shareware photographs, we chose 58 whose facial expressions appeared neutral. We created new patient images by morphing together these photographs using Photo Morpher Software (Morpheus Software, LLC, Santa Barbara, Calif, USA). The 21 best quality images were chosen and 19 independent evaluators (physicians, research assistants, and graduate students of various racial/ethnic backgrounds and not involved in the study) reviewed these. We chose four (two black and two white) that were most closely matched on apparent age (approximately 50 years) and attractiveness (7-point scale). The vignette (see Appendix) describes a 50-year-old male presenting to the emergency department with chest pain and an electrocardiogram suggestive of anterior myocardial infarction. It is stated that primary angioplasty is not an option and no absolute contraindications to thrombolysis are evident.
We asked participants to rate the likelihood that the chest pain was because of coronary artery disease (CAD) (5-point scale, very unlikely to very likely), whether they would give the patient thrombolysis (yes/no), and the strength of their recommendation (5-point scale, definitely to definitely not). To assess explicit bias, the software then asked participants several questions about whether they preferred white or black Americans (5-point scale with preference expressed as somewhat or slightly prefer black or white Americans, and 10-point thermometer scale of warm feelings toward each group separately). We also asked about their beliefs about patients’ cooperativeness in general and with regard to medical procedures such as thrombolysis (5-point scale—black patients somewhat less cooperative, slightly less cooperative, equally cooperative; white patients slightly less cooperative or somewhat less cooperative). Finally, the online survey included queries about respondent demographics, effectiveness of thrombolysis, and pre- and posttest opinions on unconscious bias and IATs. The vignettes and survey are available upon request.
Participants also completed three IATs corresponding to the explicit bias questions. The Race Preference IAT measured implicit association of white and black race with good and bad terms. We created the next two IATs specifically for this study. The Race Cooperativeness IAT measured implicit associations between race and general cooperativeness. The Race Medical Cooperativeness IAT measured implicit associations between race and cooperativeness with medical recommendations. All IAT scores are expressed as normally distributed continuous variables. For efficiency we used a 5-block structure for the IATs, with the specific pairing received first (e.g., black-bad/white-good) counterbalanced across participants. We scored IATs according to published guidelines with zero representing no racial bias, positive values representing prowhite bias, and negative scores representing problack bias (range typically −0.6 to 1.2).21 (link) Figure 1 shows the faces representing white or black race and the terms used as stimuli for the concepts of good/bad and cooperativeness/uncooperativeness.
Publication 2007
African American Angioplasty Anterior Wall Myocardial Infarction Bias, Implicit Chest Pain Coronary Artery Disease Electrocardiography Ethnicity Face Feelings Fibrinolytic Agents Indirect Coombs Test Males Negroes Patients Physicians Student Thermometers
Data were obtained from MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands)14 (link) and the IMS (Interventional Management of Stroke) III trial.15 (link) Anonymized trial data and methods that support our study findings are available for MR CLEAN upon reasonable request to mrclean@erasmusmc.nl and via the public dataset through National Institutes of Health for the IMS III trial (https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-Research/Archived-Clinical-Research-Datasets).
MR CLEAN was a phase III, multicenter, open-label RCT that evaluated the efficacy and safety of EVT plus usual care (intervention) compared with usual care alone (control) in patients with acute ischemic stroke. MR CLEAN enrolled 500 patients from 16 intervention centers in the Netherlands between December 2010 and March 2014. Enrolled patients were aged ≥18 years, had an ischemic stroke due to an intracranial large vessel occlusion in the anterior circulation with an NIHSS score of ≥2, and were able to undergo EVT within 6 hours after symptom onset. The central medical ethics committee and research board of each participating center approved this study. All patients or their legal representatives provided written informed consent before randomization.
The IMS III trial was a phase III, multicenter, open-label RCT, evaluating whether EVT combined with intravenous thrombolysis (IVT) with recombinant tissue-type plasminogen activator in a dose of 0.6 mg/kg (intervention) within 3 hours of symptom onset was superior to IVT alone (control). The IMS III trial enrolled 656 patients from 58 international centers between August 2006 and April 2012, aged 18 to 80 years with a moderate-to-severe ischemic stroke (NIHSS ≥10) before initiation of IVT. The study was approved by the ethics committee and research board of each participating center. Written informed consent was obtained from patients or their legal representative before enrollment in the study.
Publication 2019
Acute Ischemic Stroke Blood Vessel Cerebrovascular Accident Dental Occlusion Ethics Committees Fibrinolytic Agents Patients PLAT protein, human Safety Stroke, Ischemic

Most recents protocols related to «Fibrinolytic Agents»

We retrospectively identified consecutive patients admitted to the Stroke Unit of the University Hospital of Ancona, Italy, from January 2017 to April 2021 for acute ischemic stroke treated with IV thrombolysis. Each patient underwent routine blood sampling at admission (within 24 h of admission). Supplementary Table 1 provides an overview of the eligibility criteria.
The study was approved by the ethics committee of the Marche Polytechnic University (ID 57/2020) and conducted according to the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study or their representatives.
Full text: Click here
Publication 2023
Acute Ischemic Stroke Cerebrovascular Accident Eligibility Determination Ethics Committees Fibrinolytic Agents Patients
Following popliteal access (required with the use of ultrasound guidance) or femoral access with a 10-F sheath under local anaesthesia and strict sterile techniques, RT using a ZelanteDVT catheter or a Solent catheter was performed for pharmacomechanical thrombus fragmentation, suction or aspiration. First, the RT catheter was slowly advanced through the thrombotic segment (only submerged in vessel diameter estimated > 6 mm). For patients without contraindications of thrombolysis, 3 mg of rt-PA [total injected volume of 50 ml] was intraclot injected under the Power Pulse® model. After 20 minutes of dwell time, with the pump unit active during slow catheter passages (3 mm/s to 5 mm/s), runs were performed across the thrombotic segment in a distal-to-proximal or adverse direction under fluoroscopic guidance. Each device activation run lasted at less than 20 seconds with breaks of 30 seconds between the runs to avoid arrhythmia, and the total run times were monitored and kept no more than 240 seconds.
Full text: Click here
Publication 2023
Alteplase Blood Vessel Cardiac Arrhythmia Catheters Femur Fibrinolytic Agents Fluoroscopy Local Anesthesia Medical Devices Neoplasm Metastasis Patients Pulse Rate Sterility, Reproductive Suction Drainage Thrombus Ultrasonography
Technical success was defined as the successful use of AngioJet RT. Thrombus score was calculated through venography imaging by two experienced interventional physicians independently depending on pre-RT, at the completion of RT or post-CDT, by adding the scores of six vein segments (common iliac vein, external iliac vein, common femoral vein, proximal and distal segments of femoral vein, and popliteal vein). Thrombus scores were 0 when the vein was patent and completely free of thrombus, 1 in condition of a partially occluded vein, and 2 in condition of a completely occluded vein (i.e., vein lumen completely occluded with massive thrombus). The score was calculated for each segment, resulting in possible total thrombus scores. The thrombus removal rate was calculated as follows: [total pre-RT scores - total completion of RT (or total post-CDT scores)]/total pre-RT scores × 100%. Thrombus removal grades were evaluated as grade III (100% thrombus removal rate with no residual clots), grade II (50–99% thrombus removal rate), and grade I (< 50% thrombus removal rate). Thrombus removal grades II and III (i.e., ≥50% thrombus removal rate) were considered clinical success [10 (link)], which consisted of primary RT success and adjunctive CDT success. The primary RT (defined as patients who did not require adjunctive CDT treatment) success was classified based on preprocedural and at completion of RT thrombus scores evaluated as grade II and grade III. Adjunctive CDT (defined as patients who required adjunctive CDT treatment) success was classified based on preprocedural thrombus scores and those at the end of adjunctive CDT that were evaluated as grade II and grade III. The requirement of necessary adjunctive PTA and/or stent placement to treat coexisting stenosis to obtain sufficient flow within the same hospital stay was recorded but not considered clinical failure.
The safety outcomes consisted of procedure-related and CDT-related complications. The former included vessel perforation or damage (such as extravasation or retention of contrast agent in the vessel wall), bradycardia, arrhythmias or acute kidney injury (AKI). With adherence to the Society of Interventional Radiology (SIR) [11 (link)], the latter feature was divided into major CDT-related complications, which were defined as intracranial bleeding or bleeding severe enough to result in death, surgery, cessation of therapy, or blood transfusion, and minor complications, which were defined as less severe bleeding manageable with local compression, sheath upsizing, and/or alterations of thrombolytic agent dose and anticoagulant dose [11 (link)]. The SIR classification of complications is listed in the Supplementary Table.
Full text: Click here
Publication 2023
Anticoagulants Blood Transfusion Blood Vessel Cardiac Arrhythmia Clotrimazole Contrast Media Fibrinolytic Agents Iliac Vein Kidney Failure, Acute Operative Surgical Procedures Patients Phlebography Physicians Retention (Psychology) Safety Stenosis Stents Therapeutics Thrombus Vein, Femoral Veins Veins, Popliteal
If residual thrombus (defined as thrombus removal grade ≤ I) was present and did not meet the exclusion criterion of thrombolytic contraindications, a continuous infusion of reduced-dose recombinant tissue plasminogen activator (rt-PA) (Alteplase; Boehringer-Ingelheim, Ingelheim am Rhein, Germany) was delivered subsequently via a multi-side hole catheter (Uni*Fuse, AngioDynamics, Boston Scientific, USA) embedding into the thrombus. Then, 17 mg/20 mg Alteplase was administered at an infusion rate of 0.01 mg/kg per hour following CDT. The maximum rate was less than 1.0 mg/h, and the total doses were less than 50 mg, as noted elsewhere [8 (link)]. CDT was discontinued when at least 80% clot lysis with restoration of flow or a serious complication occurred. Alteplase was administered only when the fibrinogen level was > 1.0 g/L.
Full text: Click here
Publication 2023
Alteplase Catheters Clotrimazole Fibrinogen Fibrinolytic Agents rhein Thrombus
The Mount Sinai Health System (MSHS) consists of 3 comprehensive stroke centers (CSCs) and 7 PSCs. Patients with suspected or confirmed (by CTA) LVO stroke are transferred from PSCs to CSCs within our system. In addition, PSCs outside of the MSHS may transfer these cases to our CSCs. Each spoke center within or outside of MSHS acts independently and has the same availability and access to EMS transfer services. They are all geographically located within the NYC metropolitan area and follow the same transfer protocols.
Since September 2019, Viz LVO has been implemented in all MSHS facilities (PCSs and CSCs); however, PSCs outside our system lack this AI-driven tool. Viz LVO is an FDA-cleared AI-powered software that provides computer-assisted triage of suspected LVOs on CTA scans. Viz LVO is trained to identify LVOs in the supraclinoid internal carotid artery (ophthalmic, choroidal, and communicating segments) and the M1 (horizontal part) of the MCA. However, it does not assess the extracranial circulation, the posterior circulation, or the infraclinoid internal carotid artery [7] . In instances where a partial or complete occlusion is suspected, or when a vessel's caliber is less than the reference threshold, an LVO is suspected, and an alert is automatically sent to the stroke team [8] (link). For every CTA scan that is processed by Viz, a positive or negative LVO notification is provided, rather than the exact location of the occlusion.
For the purposes of this study, our institutional stroke database was reviewed in order to identify all suspected/confirmed LVO patients transferred from PSCs within and outside of our healthcare system from January 2020 to December 2021. Data collected included age, gender, ethnicity, race, rates of intravenous thrombolysis and mechanical thrombectomy, baseline modified Rankin Scale (mRS) score, presenting National Institutes of Health Stroke Scale (NIHSS), and initial Alberta Stroke Program Early CT Score (ASPECTS). Primary outcomes included peripheral arrival to peripheral CTA, transfer time, and all available time metrics from peripheral CTA.
The “Viz-transfers” group includes all LVO transfers from PSCs within our system (3 spoke hospitals), while the “Non-Viz-transfers” group (control group) is comprised of all LVO transfers from PSCs that are MSHS-affiliated but belong outside of our system (4 spoke hospitals). Spokes within MSHS are empowered with Viz, while spokes outside MSHS are not Viz-empowered. For non-MSHS spokes, interventional neuroradiology (INR) team notification time after CTA depends on how fast radiology and stroke teams diagnose the LVO. For MSHS spokes, post-CTA INR team notification is instantaneous when an LVO is suspected by Viz. To minimize confounding, contemporaneous LVO transfers within and outside the MSHS were compared. Patients that were placed on an “LVO watch” due to mild symptoms were excluded. Patients with missing time metrics were also excluded. This study was approved by our local IRB with waiver of informed consent.
Publication 2023
Cerebrovascular Accident Choroid Dental Occlusion Diagnosis Ethnicity Fibrinolytic Agents Gender Internal Carotid Arteries Pancreatic Stellate Cells Patients Radionuclide Imaging SERPINA3 protein, human Thrombectomy X-Rays, Diagnostic

Top products related to «Fibrinolytic Agents»

Sourced in Germany, France
Actilyse is a laboratory equipment product manufactured by Boehringer Ingelheim. It is a recombinant tissue plasminogen activator (rt-PA) used for the in vitro analysis of fibrinolytic systems.
Sourced in United States, Austria, Japan, Belgium, United Kingdom, Cameroon, China, Denmark, Canada, Israel, New Caledonia, Germany, Poland, India, France, Ireland, Australia
SAS 9.4 is an integrated software suite for advanced analytics, data management, and business intelligence. It provides a comprehensive platform for data analysis, modeling, and reporting. SAS 9.4 offers a wide range of capabilities, including data manipulation, statistical analysis, predictive modeling, and visual data exploration.
Sourced in Germany
Rt-PA is a laboratory equipment product used in research applications. It is a recombinant tissue plasminogen activator, a protein that plays a role in the breakdown of blood clots. The core function of Rt-PA is to facilitate the conversion of plasminogen to plasmin, which is an enzyme involved in the dissolution of fibrin clots.
Sourced in United States, China, Japan, Canada, United Kingdom, Germany, Austria
The Microplate reader is a laboratory instrument designed to measure the absorbance, fluorescence, or luminescence of samples in a microplate format. It is a versatile and automated tool used for various applications in fields such as biochemistry, cell biology, and drug discovery.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Italy, Poland, India, Canada, Switzerland, Spain, China, Sweden, Brazil, Australia, Hong Kong
SPSS Statistics is a software package used for interactive or batched statistical analysis. It provides data access and management, analytical reporting, graphics, and modeling capabilities.
Sourced in United States
The Trevo is a comprehensive lab equipment product designed to assist in various scientific and research applications. It serves as a versatile tool, providing essential functionalities required for laboratory operations. The product's core function is to facilitate efficient and reliable data collection, processing, and analysis while adhering to industry standards and safety protocols.
Sourced in United States, United Kingdom, Denmark, Belgium, Spain, Canada, Austria
Stata 12.0 is a comprehensive statistical software package designed for data analysis, management, and visualization. It provides a wide range of statistical tools and techniques to assist researchers, analysts, and professionals in various fields. Stata 12.0 offers capabilities for tasks such as data manipulation, regression analysis, time-series analysis, and more. The software is available for multiple operating systems.
Sourced in United States
The Solitaire FR is a medical device designed for use in a laboratory setting. It is a flexible aspiration catheter that is intended to assist in the removal of blood clots from blood vessels. The device features a self-expanding stent that can be used to capture and remove the clot. Its core function is to provide a tool for medical professionals to perform minimally invasive clot removal procedures.
Sourced in United States, Denmark, Austria, United Kingdom, Japan, Canada
Stata version 14 is a software package for data analysis, statistical modeling, and graphics. It provides a comprehensive set of tools for data management, analysis, and reporting. Stata version 14 includes a wide range of statistical techniques, including linear regression, logistic regression, time series analysis, and more. The software is designed to be user-friendly and offers a variety of data visualization options.
Sourced in Canada
The Trevo Proview is a compact and versatile lab equipment designed for various applications. It provides a reliable and efficient solution for tasks requiring precise temperature control and monitoring. The core function of the Trevo Proview is to maintain and regulate temperature with accuracy and consistency.

More about "Fibrinolytic Agents"

Fibrinolytic Agents, also known as thrombolytics or antifibrinolytics, are substances that promote the breakdown of fibrin, the insoluble protein that forms the framework of a blood clot.
These agents play a crucial role in the management of various thrombotic disorders, such as ischemic stroke, myocardial infarction, and deep vein thrombosis.
Researchers can explore the power of Fibrinolytic Agents using PubCompare.ai's AI-powered comparison and optimization tools.
These tools allow scientists to locate the best protocols from literature, pre-prints, and patents, while enhancing reproducibility and research accuracy.
The intuitive PubCompare.ai platform can help researchers discover the ideal Fibrinolytic Agents for their projects, such as Actilyse (alteplase, rt-PA), Solitaire FR, or Trevo (Trevo Proview).
By utilizing cutting-edge AI and data analysis, researchers can optimize their use of Fibrinolytic Agents, ensuring the highest levels of efficiency and precision.
This can be particularly useful when working with various research tools and software, such as Microplate readers, SPSS Statistics, SAS 9.4, Stata 12.0, or Stata version 14.
Whether you're studying the mechanisms of Fibrinolytic Agents, exploring their therapeutic applications, or developing new protocols, PubCompare.ai's AI-powered platform can help you enhance your research, improve reproducibility, and discover the ideal solutions for your project.